Enfortumab Vedotin Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Enfortumab Vedotin Usage And Synthesis

Uses

Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable maleimidocaproylvaline-citrulline linker (SGD-1006). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma[1][2].

Synthesis

Synthesis of enfortumab vedotin

References

[1] Halford Z, et al. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. Ann Pharmacother. 2021 Jun;55(6):772-782. DOI:10.1177/1060028020960402
[2] Chang E, et al. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021 Feb 15;27(4):922-927. DOI:10.1158/1078-0432.CCR-20-2275

Enfortumab Vedotin(1346452-25-2)Related Product Information

• Durvalumab
• Denosumab
• Evolocumab
• Monalizumab
• Avelumab
• Alirocumab
• Nivolumab
• Tislelizumab
• Toripalimab
• Lambrolizumab